Is given as to how the transition from CML patients affected by a tyrosine kinase inhibitor of the first choice to TKIs
)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) und die von der CML Working Group des britischen National Cancer Research Institute (NCRI) beauftragte Newcastle University in Großbritannien gaben heute bekannt, dass sie übergekommen sind, bei einer multizentrischen, randomisierten Phase-3-Studie mit dem Namen SPIRIT 3 zusammenzuarbeiten. CAMBRIDGE, Mass. and LONDON - ( BUSINESS WIRE ) - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and of CML Working Group of the UK National Cancer Research Institute (NCRI) commissioned Newcastle University in the UK, today announced that they are come together in a multicenter, randomized Phase 3 study, called SPIRIT third The study examines the impact of switching patients with chronic myeloid leukemia (CML) treated with a tyrosine kinase inhibitor of the first choice, but not, or not sufficiently respond to the treatment, to TKIs. The NCRI expected that with the inclusion of some 1, 000 patients will begin in approximately 172 study centers in the UK in the second quarter of 2013.
"We look forward to TKIs as a treatment option to consider in this context and to assess the potential benefits of clinical, economic and quality of life perspective."
"The design of the SPIRIT 3 trial was chosen together with ARIAD so that researchers and patients in the chronic phase can develop a deeper understanding of the effective use of tyrosine kinase inhibitors with CML. It should also be clarified whether the treatment results can be improved by allowing patients with suboptimal response to imatinib or nilotinib, converted to TKIs, "said Stephen G. O'Brien, professor of hematology at the Northern Institute for Cancer Research, the Newcastle University, NCRI member and head of the SPIRIT 3 trial. "We look forward to TKIs as a treatment option to consider in this context and to assess the potential benefits of clinical, economic and quality of life perspective."
Study design and statistical analysis
In the SPIRIT 3 trial is a randomized, two-arm, multicenter study, the molecular response (MMR, major molecular response) after three years in newly diagnosed patients who were treated with imatinib, resulting in nilotinib treatment compares when patients with suboptimal or not responded after three or 12 months on treatment, receiving TKIs as "rescue medication". In the SPIRIT 3 study included adult patients with CML in chronic phase CML in whom the diagnosis was made in the last three months and not previously treated with a TKI. About 1, 000 patients are equally randomized to standard treatment with imatinib (400 mg orally once daily) or nilotinib (300 mg orally twice daily) assigned. The conversion of patients on TKIs (45 mg orally once daily) is based on defined criteria for suboptimal response, treatment failure or intolerance to first-line therapy.
The primary endpoint of the study is the proportion of patients who showed a major molecular response (MMR) in their initially assigned treatment of first choice, regardless of whether they are converted to TKIs. When doing a particular MMR by PCR analysis in peripheral blood ratio is defined BCR-ABL to ABL transcripts on the international scale of less than or equal to 0.1%.
Observations on the diseases of British Malaya (Studies from Institute for Medical Research, Federated Malay States)
Book (Kelly & Walsh, printers)
6 Medical Myths Debunked For Christmas2008-12-19 06:54:05 by cheaande
In a study published in the Christmas 2008 issue of the British Medical Journal (and not one of their prank articles), Aaron Carroll, M.D., M.S., and Rachel Vreeman, M.D., M.S., of the Indiana University School of Medicine, explore the science behind six myths commonly associated with the holidays yet relevant year-round.
Sugar makes kids hyperactive.
Suicides increase over the holidays.
Poinsettias are toxic.
You lose most of your body heat through your head.
Eating at night makes you fat
Not a good idea2005-12-01 22:01:10 by -
BBC News World Edition
Driving after taking even small amounts of cannabis almost doubles risk of a fatal road accident, research suggests.
The French National Institute for Transport and Safety Research found evidence of cannabis use among 7% of drivers involved in fatal crashes.
However, the figure was dwarfed by the 21.4% who tested positive for alcohol consumption.
The British Medical Journal study was based on 10,748 drivers involved in fatal crashes between 2001 and 2003.
Research like this proves just how dangerous it is to take drugs, and then get behind the wheel of a car
All of the drivers had compulsory tests for drugs and alcohol
Dueling Professors2007-08-18 09:46:42 by theUrbanHermit
But arguing on the other side of the debate and also featured in the British Medical Journal was Professor Ian Hickie.
Prof Hickie, of Sydney University's Brain and Mind Research Institute, said that increased levels of treatment has led to demonstrable benefits among patients, and therefore it was wrong to say that depression is being diagnosed too often.
He added that increased diagnosis and treatment had also led to a reduction in suicides and to the old stigma around mental illness being abandoned.
In addition, he said that although there have been concerns about new anti-depression drugs
They didn't pay for these studies2004-03-07 11:13:10 by ButUStillWearARespirator
Lots of research on the topic:
Treasure, T., D. Waller, et al. (2004). "Radical Surgery for Mesothelioma: The epidemic is still to peak and we need more research to manage it." British Medical Journal 328: 237-8.
Leigh, J. and T. Driscoll (2003). "Malignant mesothelioma in Australia, 1945-2002." Int J Occup Environ Health 9(3): 206-17.
Lilienfeld, D. E., J. S. Mandel, et al. (1988). "Projection of asbestos related diseases in the United States, 1985-2009. I. Cancer." Br J Ind Med 45(5): 283-91.
Lilienfeld, D. E. (1991). "Asbestos-associated pleural mesothelioma in school teachers: a discussion of four cases
You might also like:
Sudbury woman finds simple discovery of happiness — The Sudbury Star
The 29-year-old, currently in the final phase of her PhD program at the University of Ottawa and conducting research at the Advanced Medical Research Institute of Canada in Sudbury, was enlightened after volunteering at a tribal school in Orissa, India ..
Journal of a Medical and Population Genetic Survey Expedition of the Research Vessel Alpha Helix to the Banks and Torres Islands of the New Hebrides, Southern Islands of the British Solomon Islands Pretectorate and Pingelap Atoll, Eastern Caroline Islands, September 8, 1972 to November 26, 1972.
Book (Study of Child Growth and Development and Disease Patterns in Primitive Cultures / National Institute of Neurological Diseases and Blindness / National Institutes of Health)
Training Carers in Physical Interventions: Research Towards Evidence-based Practice
Book (British Institute of Learning Disabilities)
Current Research in Osteoporosis and Bone Mineral Measurement: Proceedings of the 4th Bath Conference on Osteoporosis and Bone Mineral Measurement, 21-24 June 1994
Book (British Institute of Radiology)
Efforts to Restructure a Medical Delivery System: The British National Health System (Institute for Research on Poverty Discussion Paper 620-80)
Book (University of Wisconsin--Madison, Institute for Research on Poverty)